Matt Hewitt is ranked #707 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

C-H

Matt Hewitt

Q: How accurate are Matt Hewitt's stock ratings?

About 62% of Matt's ratings were profitable over a one-year hold, with an average return of +7.5% per rating, measured by 13Foresight from historical prices.

Craig-Hallum

Wall Street Analyst

★★★★☆

#707

on 13Foresight · ranked by our own returns

62%

Success Rate

+7.5%

Average Return

52 of 84 calls profitable · +2.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 62% of Matt Hewitt's ratings turned a profit when each position was held for 1 year — averaging +7.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

268 Buy 12 Hold 0 Sell

Matt's Stock Coverage 39 ratings · 2026-08-13

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
OABI OmniAb	Aug 07, 2026	BUY	Strong Buy +127.9% avg upside 10 analysts	$7.00 104.65% Upside	+0.0%	·
CYRX CryoPort	Aug 07, 2026	BUY	Strong Buy +9.8% avg upside 15 analysts	$20.00 35.11% Upside	+0.3%	·
LGND Ligand Pharma	Aug 07, 2026	BUY	Strong Buy -6.6% avg upside 15 analysts	$370.00 26.18% Upside	-1.5%	·
CERT Certara	Aug 04, 2026	HOLD	Buy +63.3% avg upside 22 analysts	—	+2.4%	·
CDXS Codexis	Jul 24, 2026	BUY	Strong Buy +566.4% avg upside 13 analysts	—	+2.0%	·
BLFS BioLife Solutions	Jul 22, 2026	HOLD	Buy -15.5% avg upside 17 analysts	$31.00 11.45% Downside	+12.3%	·
DYAI Dyadic International	Jul 16, 2026	BUY	Buy 3 analysts	—	-35.3%	·
BHST BioHarvest Sciences	Jul 15, 2026	BUY	Strong Buy +318.6% avg upside 5 analysts	—	-10.2%	·
SDGR Schrodinger	Jul 08, 2026	BUY	Strong Buy +52.1% avg upside 14 analysts	—	+14.7%	·
SLP Simulations Plus	Jul 08, 2026	HOLD	Buy +106.8% avg upside 11 analysts	—	+0.3%	·
LFCR Lifecore Biomedical	Jul 06, 2026	BUY	Strong Buy +98.4% avg upside 10 analysts	—	-0.8%	·
MXCT MaxCyte	Jul 02, 2026	BUY	Buy +214.9% avg upside 5 analysts	—	+13.9%	·
RGEN Repligen	Jun 24, 2026	BUY	Strong Buy +4.7% avg upside 25 analysts	—	+20.0%	·
TKNO Alpha Teknova	Jun 24, 2026	BUY	Strong Buy +81.2% avg upside 7 analysts	—	+42.1%	·
OMCL Omnicell	Jun 11, 2026	BUY	Strong Buy +32.0% avg upside 12 analysts	—	-1.6%	·
RZLT Rezolute	Jun 02, 2026	HOLD	Strong Buy +126.0% avg upside 13 analysts	—	+17.0%	·
PARK Park Dental Partners, Inc.	Jun 02, 2026	BUY	Strong Buy +2.9% avg upside 2 analysts	—	+6.0%	·
INFU InfuSystem Holdings	May 19, 2026	BUY	Strong Buy +30.9% avg upside 7 analysts	—	+26.6%	·
APYX Apyx Medical	May 08, 2026	BUY	Strong Buy +789.7% avg upside 11 analysts	$6.00 100.66% Upside	-17.2%	·
MRVI Maravai Lifesciences Holdings	May 08, 2026	BUY	Strong Buy +148.3% avg upside 17 analysts	$5.00 13.49% Downside	+19.2%	·
HSTM HealthStream	May 06, 2026	BUY	Buy +11.6% avg upside 8 analysts	$40.00 40.98% Upside	+24.2%	·
BZAI Blaize Holdings	Mar 25, 2026	BUY	Strong Buy +302.8% avg upside 6 analysts	—	-11.3%	·
CSBR Champions Oncology	Dec 16, 2025	BUY	Strong Buy +71.7% avg upside 6 analysts	$12.00 142.34% Upside	-22.9%	·
VUZI Vuzix	Dec 09, 2025	BUY	Strong Buy +162.4% avg upside 8 analysts	—	-12.3%	·
CLOV Clover Health Investments	Oct 10, 2025	BUY	Hold -18.2% avg upside 9 analysts	—	+85.9%	·
FSLY Fastly	Jun 17, 2025	HOLD	Buy +17.0% avg upside 26 analysts	—	+162.6%	·
NEO NeoGenomics	Apr 25, 2025	BUY	Strong Buy +4.6% avg upside 18 analysts	—	-19.3%	·
BWMN Bowman Consulting Group	Mar 18, 2025	BUY	Buy +6.5% avg upside 11 analysts	—	+12.5%	·
EHTH Ehealth	Dec 18, 2024	BUY	Hold +1174.9% avg upside 19 analysts	—	-37.2%	·
ISPC iSpecimen	Aug 07, 2024	BUY	Strong Buy +87.2% avg upside 3 analysts	—	·	·
SRTS Sensus Healthcare	Feb 09, 2024	BUY	Buy +115.8% avg upside 8 analysts	$6.00 91.79% Upside	+50.4%	·
TSE:ELVA Electrovaya	Sep 21, 2023	BUY	Strong Buy +67.9% avg upside 11 analysts	—	-20.1%	·
VIAOY VIA optronics	Aug 30, 2023	BUY	Strong Buy +5733.4% avg upside 3 analysts	—	·	·
TDOC Teladoc	Feb 23, 2023	HOLD	Buy +330.2% avg upside 38 analysts	—	-47.1%	·
ANGO AngioDynamics	Oct 04, 2019	HOLD	Strong Buy +12.9% avg upside 9 analysts	$17.00 8.02% Upside	-21.2%	·
VIVE Viveve Medical	Jan 18, 2019	HOLD	Buy +79999900.0% avg upside 8 analysts	$100.00 49999899.95% Upside	·	·
TECH Bio-Techne	Oct 31, 2018	HOLD	Buy +15.5% avg upside 21 analysts	$154.00 113.25% Upside	+25.0%	·
MDXG MiMedx Group	Feb 27, 2018	BUY	Strong Buy +149.8% avg upside 17 analysts	$19.00 343.94% Upside	-59.4%	·
HAE Haemonetics	Nov 08, 2017	HOLD	Buy -15.0% avg upside 18 analysts	$50.00 45.19% Downside	+112.2%	·

🔒 34 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Matt Hewitt — Frequently Asked Questions

How accurate are Matt Hewitt's stock ratings?

Based on the calls 13Foresight could measure, about 62% of Matt's ratings were profitable over a one-year hold, with an average return of +7.5% per rating, or +2.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Matt ranked on 13Foresight?

Matt Hewitt is currently ranked #707 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Matt cover?

Matt most recently has ratings on OABI, CYRX, LGND, CERT, CDXS, BLFS, DYAI, BHST, SDGR, SLP, LFCR, MXCT and 27 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Matt Hewitt

Rating Distribution

Welcome to 13Foresight!